Figure 4.
Effects of oligos on the growth of human lung cancer A549 xenografts in C.B-17-scid/scid mice. Each point represents the mean ± SE of tumor mass from six mice. Oligo AS, administered orally at 0.5, 5, and 10 mg/kg per day at five doses per week, demonstrated dose-dependent antitumor activity. Oligo ASM has no effect, confirming the specificity of Oligo AS.
